Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet

Boehringer Ingelheim

Status: Completed

Conditions: Rhinitis, Allergic, Perennial

Treatments: Drug: Alesion®

Study type: Observational

Funder types: Industry

Identifiers

NCT02238223

262.290

Details and patient eligibility

About

Study to investigate the safety and efficacy information of Alesion® Tablet under the proper use in daily clinical practice after new treatment guideline for allergic rhinitis, bronchial asthma, eczema, dermatitis, urticaria, pruritus, prurigo and psoriasis vulgaris with itching

Enrollment: 2,001 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

All the patients who:

• haven't treatment experience of epinastine product;
• have at least one out of following diseases. allergic rhinitis, eczema, dermatitis, pruritus, prurigo, urticaria, psoriasis with itching, bronchial asthma

Exclusion criteria

• Alesion® Tablet is contraindicated for the patients with history of hypersensitivity to any ingredients of Alesion® Tablet in package insert. However, it is unknown whether a patient is hypersensitive to the ingredients of the product in almost cases. And this survey is drug utilization study to observe actual use in any patients. Therefore exclusion criteria is not set in the protocol

Trial design

2,001 participants in 1 patient group

Patients without experience in treatment with epinastine

Treatment:

Drug: Alesion®